Analysts view Legend Biotech's current valuations as a buying opportunity.
1 report, 0 independent
Updated Jun 26
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Analysts view Legend Biotech's current valuations as a buying opportunity.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Royal Bank of Canada cut its price target on Legend Biotech in a research report.Sub-event
- Analysts view Legend Biotech's valuation as a buying opportunity.
Keep exploring
The entities involved
-
Legend Biotech
Biotech company
Nothing else this week.
-
Royal Bank of Canada
financial institution in Canada
Related events
- RBC raised its price objective and Raymond James Financial restated an outperform rating for Vulcan on August 26, 2026.
- Royal Bank of Canada purchased shares of Capital Research Global Investors on August 27, 2026, amid increased institutional investor stakes.
- Royal Bank of Canada lowered its target price for Arthur J. Gallagher & Co. in a research report.
- RBC raised price targets for Lineage stock on August 1, 2026.
- Royal Bank of Canada increased its target price for Sun Life Financial.
Coverage
Newest first; wire copies grouped- Unknown outlet